Quoin Pharma Surges 45% In Pre-Market On Positive QRX003 Data And $50M Private Placement

Quoin Pharmaceuticals (QNRX) reported positive interim results from its Phase 2/3 study of QRX003 for Netherton Syndrome. Four of six patients showed significant improvement. The company expects to complete recruitment by the end of 2026 and report topline data in Q2 2027. If approved, QRX003 could be the first FDA-approved treatment for the condition. QNRX shares rose 55% to $7.99 in pre-market trading.

Quoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Com

Quoin Pharmaceuticals said the FDA cleared its IND for QRX003 to start a Phase II trial for Peeling Skin Syndrome. The study is expected to begin in 2H 2026, enrolling 6 to 8 patients in the US and Europe. Patients will apply the topical lotion twice daily to over 80% of body surface for 52 weeks. Quoin targets approval in 2028.

Quoin Pharmaceuticals (QNRX) said the FDA cleared its IND for QRX003 in Peeling Skin Syndrome, allowing it to start a planned Phase 2 trial. The study is expected to begin in 2H 2026, enrolling 6-8 patients and dosing twice daily for 52 weeks. The company cited no FDA safety concerns and prior investigator-led pediatric results showing improvements by Week 12.

Quoin Pharmaceuticals (NASDAQ: QNRX) said the FDA cleared its IND for QRX003 to start a Phase 2 study for Peeling Skin Syndrome. The trial is expected to begin in 2H 2026 and enroll 6-8 pediatric and adult patients in the US and Europe. FDA reported no safety concerns on design and dosing duration. Quoin targets approval in 2028.

Quoin Pharmaceuticals said it filed an IND with the FDA for QRX003 to treat Peeling Skin Syndrome, based on results from an ongoing investigator-led pediatric study. The company expects to start a Phase 2 trial in the second half of 2026 after FDA review. It reported improvements in skin, sleep and quality of life, and said QRX003 was well tolerated.